Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine Ophthalmic Solution in Pediatric Allergic Conjunctivitis
NCT04810390Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bilastine in allergic conjunctivitis (AC), sponsored by Faes Farma. Started Mar 2021; status: completed.
02
Drugs
bilastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04810390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810390.